

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Pomalyst (pomalidomide)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limits
Pomalyst (pomalidomide)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Pomalyst (pomalidomide) may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsed/refractory Multiple Myeloma; **AND**
- II. Individual is using in combination with dexamethasone; **AND**
- III. Individual has demonstrated disease progression on or within 60 days of completion of the last therapy; **AND**
- IV. Individual has had a trial of at least two prior therapies, including lenalidomide and protease inhibitor;

OR

- V. Individual has a diagnosis of systemic light chain amyloidosis and is using in combination with dexamethasone (NCCN 2A);

OR

- VI. Individual has a diagnosis of relapsed/refractory advanced, cutaneous, oral, visceral, or nodal AIDS-Related Kaposi Sarcoma disease; **AND**
- VII. Individual has progressed on or not responded to first-line systemic therapy **AND** progressed on alternate first-line systemic therapy.

Note: Pomalyst (pomalidomide) has a black box warning noting that, as a thalidomide analogue, pomalidomide is contraindicated in pregnancy. Thalidomide is a known human teratogen causing severe life-threatening birth defects. In addition, pomalidomide may cause deep venous thrombosis (DVT) and pulmonary embolism (PE).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.